Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Therapeutic monoclonal antibodies in human breast milk: a case study.

Ross E, Robinson SE, Amato C, McMillan C, Westcott J, Wolf T, Robinson WA.

Melanoma Res. 2014 Apr;24(2):177-80. doi: 10.1097/CMR.0000000000000047.

PMID:
24476799
2.

Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.

Woźniak S, Mackiewicz-Wysocka M, Krokowicz Ł, Kwinta Ł, Mackiewicz J.

Oncol Res Treat. 2015;38(3):105-8. doi: 10.1159/000377650.

PMID:
25792081
3.

Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.

Kopecký J, Trojanová P, Kubeček O, Kopecký O.

Jpn J Clin Oncol. 2015 Apr;45(4):381-4. doi: 10.1093/jjco/hyu222. Review.

PMID:
25583422
4.

[Ipilimumab treatment of metastatic melanoma].

Ghasemi H, Schmidt H, Stolle LB.

Ugeskr Laeger. 2015 Jan 26;177(2A):108-9. Danish.

PMID:
25612993
5.

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.

Kähler KC, Hauschild A.

J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86. doi: 10.1111/j.1610-0387.2010.07568.x. Review. English, German.

PMID:
21083648
6.

A case report of orbital inflammatory syndrome secondary to ipilimumab.

Henderson AD, Thomas DA.

Ophthal Plast Reconstr Surg. 2015 May-Jun;31(3):e68-70. doi: 10.1097/IOP.0000000000000081.

PMID:
24814274
7.

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.

Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D.

Chest. 2013 Mar;143(3):858-61. doi: 10.1378/chest.12-1467.

PMID:
23460165
8.

Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.

O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS.

AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032. Review.

PMID:
21785048
9.

Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.

Koch C, Paetzold S, Trojan J.

Gastroenterology. 2012 Aug;143(2):298, 504, 505. doi: 10.1053/j.gastro.2012.01.042. No abstract available.

PMID:
22709738
10.

[Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma -  a Case Report].

Kopecký J, Kubeček O, Gabalec F, Hoffmann P, Svilias I.

Klin Onkol. 2015;28(6):444-9. Czech.

PMID:
26673995
11.

Nursing management of patients with metastatic melanoma receiving ipilimumab.

Bryce J, Passoni C.

Oncol Nurs Forum. 2013 May 1;40(3):215-8. doi: 10.1188/13.ONF.215-218. No abstract available.

PMID:
23615135
12.

Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.

Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST.

Arch Dermatol. 2006 Feb;142(2):166-72.

PMID:
16490844
13.

Agents make "preferred list" in metastatic melanoma.

Thompson JA.

J Natl Compr Canc Netw. 2014 May;12(5 Suppl):785-7.

PMID:
24853217
14.

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.

Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA.

J Clin Oncol. 2015 Nov 20;33(33):e122-4. doi: 10.1200/JCO.2013.51.1683. No abstract available.

15.

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB.

Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227.

16.

Ipilimumab-induced perforating colitis.

Mitchell KA, Kluger H, Sznol M, Hartman DJ.

J Clin Gastroenterol. 2013 Oct;47(9):781-5. doi: 10.1097/MCG.0b013e31828f1d51.

PMID:
23632354
17.

Ipilimumab-induced immune-related renal failure--a case report.

Forde PM, Rock K, Wilson G, O'Byrne KJ.

Anticancer Res. 2012 Oct;32(10):4607-8.

PMID:
23060594
18.

Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma.

Wilkes GM.

Oncology (Williston Park). 2011 Jul;25(7 Suppl Nurse Ed):46-7. No abstract available.

PMID:
25373277
19.

Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.

Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, Schmidt RE, Pestronk A.

Muscle Nerve. 2013 Sep;48(3):440-4. doi: 10.1002/mus.23830.

PMID:
23447136
20.

Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.

Kyllo RL, Parker MK, Rosman I, Musiek AC.

J Am Acad Dermatol. 2014 Apr;70(4):e85-6. doi: 10.1016/j.jaad.2013.11.022. Review. No abstract available.

Items per page

Supplemental Content

Support Center